Talk amongst the industry may indicate that Shire is losing faith in its ill-considered attempt to take out newly spun out Baxalta as the biotech continues to thwart any takeout talk. Speculation has emerged that Shire is looking into other potential targets, including Ariad Pharmaceuticals, Actelion Pharmaceuticals and Radius Health.
It's been widely talked about that Shire's $34bn offer for the newly-formed Baxalta is financially motivated and not necessarily strategically sound. The big biotech announced the morning of Aug....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?